{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:45:40Z","timestamp":1793270740545,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40259-025-00723-3","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T10:07:45Z","timestamp":1746094065000},"page":"517-535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Progress and Challenges in the Treatment of Fabry Disease"],"prefix":"10.1007","volume":"39","author":[{"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise Raphaela","family":"Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"723_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008;372:1427\u201335.","journal-title":"Lancet"},{"key":"723_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31\u201340.","journal-title":"Am J Hum Genet"},{"key":"723_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","volume":"60","author":"M Gilchrist","year":"2023","unstructured":"Gilchrist M, Casanova F, Tyrrell JS, et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2023;60:391\u20136.","journal-title":"J Med Genet"},{"key":"723_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"723_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44\u201354.","journal-title":"Clin Genet"},{"key":"723_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416\u201327.","journal-title":"Mol Genet Metab"},{"key":"723_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"723_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124:189\u2013203.","journal-title":"Mol Genet Metab"},{"key":"723_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13023-024-03500-7","volume":"20","author":"E Brand","year":"2025","unstructured":"Brand E, Linhart A, Deegan P, et al. Clinical management of female patients with Fabry disease based on expert consensus. Orphanet J Rare Dis. 2025;20:7.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR12","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.3390\/biomedicines12112578","volume":"12","author":"DP Germain","year":"2024","unstructured":"Germain DP, Porto Vasconcelos A, Tran Thi Phuong L, et al. Safety and tolerability of a shorter agalsidase beta infusion time in patients with classic or later-onset Fabry disease. Biomedicines. 2024;12:2578.","journal-title":"Biomedicines."},{"key":"723_CR13","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2265\u201378.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"723_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12325-024-03041-2","volume":"42","author":"R Mignani","year":"2025","unstructured":"Mignani R, Biagini E, Cianci V, et al. Effects of current therapies on disease progression in Fabry disease: a narrative review for better patient management in clinical practice. Adv Ther. 2025;42(2):597\u2013635. https:\/\/doi.org\/10.1007\/s12325-024-03041-2.","journal-title":"Adv Ther"},{"key":"723_CR15","doi-asserted-by":"publisher","DOI":"10.1148\/ryct.230154","volume":"6","author":"S Figliozzi","year":"2024","unstructured":"Figliozzi S, Kollia E, Simistiras A, et al. Effects of enzyme replacement therapy on cardiac MRI findings in Fabry disease: a systematic review and meta-analysis. Radiol Cardiothorac Imaging. 2024;6: e230154.","journal-title":"Radiol Cardiothorac Imaging."},{"key":"723_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","volume":"10","author":"C Kampmann","year":"2015","unstructured":"Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years\u2019 treatment. Orphanet J Rare Dis. 2015;10:125.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52:353\u20138.","journal-title":"J Med Genet"},{"key":"723_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s10545-015-9845-5","volume":"38","author":"R Schiffmann","year":"2015","unstructured":"Schiffmann R, Swift C, Wang X, Blankenship D, Ries M. A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease. J Inherit Metab Dis. 2015;38:1129\u201336.","journal-title":"J Inherit Metab Dis"},{"key":"723_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-016-0473-4","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, Hennermann JB, Kurschat C, et al. Multicenter Female Fabry Study (MFFS): clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11:88.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s13023-024-03503-4","volume":"19","author":"M Lenders","year":"2024","unstructured":"Lenders M, Nowak A, Cybulla M, et al. Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease. Orphanet J Rare Dis. 2024;19:490.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-025-03600-y","volume":"20","author":"M Lenders","year":"2025","unstructured":"Lenders M, Nowak A, Cybulla M, et al. Impact of enzyme replacement therapy and migalastat on disease progression in females with Fabry disease. Orphanet J Rare Dis. 2025;20:79.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR22","volume":"19","author":"DP Germain","year":"2019","unstructured":"Germain DP, Elliott PM, Falissard B, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19: 100454.","journal-title":"Mol Genet Metab Rep."},{"key":"723_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24:137\u201348.","journal-title":"J Am Soc Nephrol"},{"key":"723_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1681\/ASN.2013060585","volume":"25","author":"F Weidemann","year":"2014","unstructured":"Weidemann F, Kr\u00e4mer J, Duning T, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol. 2014;25:837\u201349.","journal-title":"J Am Soc Nephrol"},{"key":"723_CR25","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1681\/ASN.2015030337","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Canaan-K\u00fchl S, Kr\u00e4mer J, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up. J Am Soc Nephrol. 2016;27:952\u201362.","journal-title":"J Am Soc Nephrol"},{"key":"723_CR26","first-page":"807","volume":"32","author":"R Skrunes","year":"2017","unstructured":"Skrunes R, Svarstad E, Kampevold Larsen K, Leh S, T\u00f8ndel C. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrol Dial Transplant. 2017;32:807\u201313.","journal-title":"Nephrol Dial Transplant"},{"key":"723_CR27","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","volume":"33","author":"J Kr\u00e4mer","year":"2018","unstructured":"Kr\u00e4mer J, Lenders M, Canaan-K\u00fchl S, et al. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages. Nephrol Dial Transplant. 2018;33:1362\u201372.","journal-title":"Nephrol Dial Transplant"},{"key":"723_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymgme.2022.10.005","volume":"137","author":"C T\u00f8ndel","year":"2022","unstructured":"T\u00f8ndel C, Thurberg BL, DasMahapatra P, et al. Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. Mol Genet Metab. 2022;137:328\u201341.","journal-title":"Mol Genet Metab"},{"key":"723_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ymgme.2018.07.009","volume":"125","author":"H Morimoto","year":"2018","unstructured":"Morimoto H, Ito Y, Yoden E, et al. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease. Mol Genet Metab. 2018;125:153\u201360.","journal-title":"Mol Genet Metab"},{"key":"723_CR30","volume":"40","author":"T Tsukimura","year":"2024","unstructured":"Tsukimura T, Shiga T, Togawa T, Sakuraba H. Comparative study on incorporation of three recombinant human \u03b1-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs\/tissues of Fabry mice. Mol Genet Metab Rep. 2024;40: 101118.","journal-title":"Mol Genet Metab Rep."},{"key":"723_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ymgme.2020.04.003","volume":"130","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Kawashima S, Tozawa H, et al. Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II\/III clinical studies. Mol Genet Metab. 2020;130:215\u201324.","journal-title":"Mol Genet Metab"},{"key":"723_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40268-023-00421-x","volume":"23","author":"ABP van Kuilenburg","year":"2023","unstructured":"van Kuilenburg ABP, Hollak CEM, Travella A, et al. Development of a biosimilar of agalsidase beta for the treatment of Fabry disease: preclinical evaluation. Drugs R D. 2023;23:141\u201353.","journal-title":"Drugs R D."},{"key":"723_CR33","volume":"41","author":"V Berstein","year":"2024","unstructured":"Berstein V, Pirotzky EM, Taconelli HD, et al. Comparative pharmacokinetics and pharmacodynamics of two formulations of agalsidase beta (agalsidase Biosidus) and Fabrazyme\u00ae by intravenous infusion in healthy male volunteers. Mol Genet Metab Rep. 2024;41: 101149.","journal-title":"Mol Genet Metab Rep."},{"key":"723_CR34","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/acs.bioconjchem.8b00133","volume":"29","author":"I Ruderfer","year":"2018","unstructured":"Ruderfer I, Shulman A, Kizhner T, et al. Development and analytical characterization of pegunigalsidase alfa, a chemically cross-linked plant recombinant human \u03b1-galactosidase-A for treatment of Fabry disease. Bioconjug Chem. 2018;29:1630\u20139.","journal-title":"Bioconjug Chem"},{"key":"723_CR35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1\/2 clinical trial. J Inherit Metab Dis. 2019;42:534\u201344.","journal-title":"J Inherit Metab Dis"},{"key":"723_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12795","volume":"48","author":"M Holida","year":"2025","unstructured":"Holida M, Linhart A, Pisani A, et al. A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. J Inherit Metab Dis. 2025;48: e12795.","journal-title":"J Inherit Metab Dis"},{"key":"723_CR37","doi-asserted-by":"publisher","first-page":"1395287","DOI":"10.3389\/fgene.2024.1395287","volume":"15","author":"DP Germain","year":"2024","unstructured":"Germain DP, Linhart A. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease. Front Genet. 2024;15:1395287.","journal-title":"Front Genet"},{"key":"723_CR38","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61:520\u201330.","journal-title":"J Med Genet"},{"key":"723_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis. 2023;18:332.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, et al. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27:256\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"723_CR41","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/jmg-2023-109818","volume":"61","author":"M Lenders","year":"2024","unstructured":"Lenders M, Brand E. Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity. J Med Genet. 2024;61:531\u20133.","journal-title":"J Med Genet"},{"key":"723_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40259-024-00690-1","volume":"39","author":"M Lenders","year":"2025","unstructured":"Lenders M, Menke ER, Rudnicki M, Cybulla M, Brand E. Relevance of neutralizing antibodies for the pharmacokinetics of pegunigalsidase alfa in patients with Fabry disease. BioDrugs. 2025;39:153\u201365.","journal-title":"BioDrugs"},{"key":"723_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19:430\u20138.","journal-title":"Genet Med"},{"key":"723_CR44","volume":"28","author":"DG Bichet","year":"2021","unstructured":"Bichet DG, Torra R, Wallace E, et al. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. Mol Genet Metab Rep. 2021;28: 100786.","journal-title":"Mol Genet Metab Rep."},{"key":"723_CR45","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/jmg-2022-108669","volume":"60","author":"DA Hughes","year":"2023","unstructured":"Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. J Med Genet. 2023;60:722\u201331.","journal-title":"J Med Genet"},{"key":"723_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0314030","volume":"19","author":"FK Johnson","year":"2024","unstructured":"Johnson FK, Wu S, Schmith G, et al. Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment. PLoS ONE. 2024;19: e0314030.","journal-title":"PLoS ONE"},{"key":"723_CR47","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2119\/molmed.2015.00088","volume":"21","author":"KM Ashe","year":"2015","unstructured":"Ashe KM, Budman E, Bangari DS, et al. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol Med. 2015;21:389\u201399.","journal-title":"Mol Med"},{"key":"723_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Gu\u00e9rard","year":"2018","unstructured":"Gu\u00e9rard N, Oder D, Nordbeck P, et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther. 2018;103:703\u201311.","journal-title":"Clin Pharmacol Ther"},{"key":"723_CR49","volume":"31","author":"C Wanner","year":"2022","unstructured":"Wanner C, Kimonis V, Politei J, et al. Understanding and modifying Fabry disease: rationale and design of a pivotal phase 3 study and results from a patient-reported outcome validation study. Mol Genet Metab Rep. 2022;31: 100862.","journal-title":"Mol Genet Metab Rep."},{"key":"723_CR50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.865","volume":"10","author":"MJ Peterschmitt","year":"2021","unstructured":"Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT. Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10:86\u201398.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"723_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.11.002","volume":"138","author":"PB Deegan","year":"2023","unstructured":"Deegan PB, Goker-Alpan O, Geberhiwot T, et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. Mol Genet Metab. 2023;138: 106963.","journal-title":"Mol Genet Metab"},{"key":"723_CR52","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/cpdd.1375","volume":"13","author":"M Babcock","year":"2024","unstructured":"Babcock M, Zheng J, Gail Shurr J, et al. Phase 1 healthy volunteer study of AL01211, an oral, non-brain penetrant glucosylceramide synthase inhibitor, to treat Fabry disease and type 1 Gaucher disease. Clin Pharmacol Drug Dev. 2024;13:696\u2013709.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"723_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40261-024-01362-2","volume":"44","author":"L Dong","year":"2024","unstructured":"Dong L, Xiang J, Babcock M, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral AL01211 in healthy Chinese volunteers. Clin Drug Investig. 2024;44:387\u201398.","journal-title":"Clin Drug Investig"},{"key":"723_CR54","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32:1529\u201341.","journal-title":"Leukemia"},{"key":"723_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70073","volume":"15","author":"A Khan","year":"2025","unstructured":"Khan A, Barber DL, McKillop WM, et al. Lentivirus-mediated gene therapy for Fabry disease: 5-year end-of-study results from the Canadian FACTs trial. Clin Transl Med. 2025;15: e70073.","journal-title":"Clin Transl Med"},{"key":"723_CR56","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","volume":"12","author":"A Khan","year":"2021","unstructured":"Khan A, Barber DL, Huang J, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun. 2021;12:1178.","journal-title":"Nat Commun"},{"key":"723_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJM200301163480314","volume":"348","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255\u20136.","journal-title":"N Engl J Med"},{"key":"723_CR58","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Investig. 2008;118:3132\u201342.","journal-title":"J Clin Investig"},{"key":"723_CR59","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1172\/JCI35798","volume":"118","author":"SJ Howe","year":"2008","unstructured":"Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Investig. 2008;118:3143\u201350.","journal-title":"J Clin Investig"},{"key":"723_CR60","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.omtm.2023.01.003","volume":"28","author":"AH Saleh","year":"2023","unstructured":"Saleh AH, Rothe M, Barber DL, et al. Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease. Mol Ther Methods Clin Dev. 2023;28:262\u201371.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"723_CR61","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymgme.2021.11.316","volume":"135","author":"M Thomas","year":"2022","unstructured":"Thomas M. Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease. Mol Genet Metab. 2022;135:119.","journal-title":"Mol Genet Metab"},{"key":"723_CR62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317\u201334.","journal-title":"BioDrugs"},{"key":"723_CR63","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342\u20137.","journal-title":"Nat Med"},{"key":"723_CR64","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Maus MV, Hui DJ, et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13:419\u201322.","journal-title":"Nat Med"},{"key":"723_CR65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40265-023-01836-1","volume":"83","author":"HCJ Ertl","year":"2023","unstructured":"Ertl HCJ. Mitigating serious adverse events in gene therapy with AAV vectors: vector dose and immunosuppression. Drugs. 2023;83:287\u201398.","journal-title":"Drugs"},{"key":"723_CR66","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/mt.2011.108","volume":"19","author":"V Monteilhet","year":"2011","unstructured":"Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther. 2011;19:2084\u201391.","journal-title":"Mol Ther"},{"key":"723_CR67","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","volume":"16","author":"A Orlowski","year":"2020","unstructured":"Orlowski A, Katz MG, Gubara SM, Fargnoli AS, Fish KM, Weber T. Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption. Mol Ther Methods Clin Dev. 2020;16:192\u2013203.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"723_CR68","doi-asserted-by":"publisher","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","volume":"5","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, Anguela XM, Pavani G, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med. 2013;5:194ra92.","journal-title":"Sci Transl Med."},{"key":"723_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034684","volume":"7","author":"J Karman","year":"2012","unstructured":"Karman J, Gumlaw NK, Zhang J, Jiang JL, Cheng SH, Zhu Y. Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors. PLoS ONE. 2012;7: e34684.","journal-title":"PLoS ONE"},{"key":"723_CR70","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/172458","volume":"2015","author":"F Accardi","year":"2015","unstructured":"Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N. Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling. Biomed Res Int. 2015;2015: 172458.","journal-title":"Biomed Res Int"},{"key":"723_CR71","doi-asserted-by":"publisher","first-page":"14033","DOI":"10.1038\/mtm.2014.33","volume":"1","author":"M Corti","year":"2014","unstructured":"Corti M, Elder M, Falk D, et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev. 2014;1:14033.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"723_CR72","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.omtm.2020.06.003","volume":"18","author":"X Pei","year":"2020","unstructured":"Pei X, Shao W, Xing A, et al. Development of AAV variants with human hepatocyte tropism and neutralizing antibody escape capacity. Mol Ther Methods Clin Dev. 2020;18:259\u201368.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"723_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.107152","volume":"138","author":"RJ Hopkin","year":"2023","unstructured":"Hopkin RJ, Ganesh J, Deegan P, et al. STAAR, a phase I\/II study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: dose escalation phase results. Mol Genet Metab. 2023;138: 107152.","journal-title":"Mol Genet Metab"},{"key":"723_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107884","volume":"141","author":"RJ Hopkin","year":"2024","unstructured":"Hopkin RJ, Ganesh J, Bernat J, et al. Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: updated results from an ongoing phase 1\/2 study (STAAR). Mol Genet Metab. 2024;141: 107739.","journal-title":"Mol Genet Metab"},{"key":"723_CR75","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","volume":"30","author":"JM Jeyakumar","year":"2023","unstructured":"Jeyakumar JM, Kia A, Tam LCS, et al. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023;30:487\u2013502.","journal-title":"Gene Ther"},{"key":"723_CR76","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.recesp.2023.06.016","volume":"76","author":"A Argir\u00f2","year":"2023","unstructured":"Argir\u00f2 A, Ding J, Adler E. Gene therapy for heart failure and cardiomyopathies. Rev Esp Cardiol (Engl Ed). 2023;76:1042\u201354.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"723_CR77","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","volume":"27","author":"F DeRosa","year":"2019","unstructured":"DeRosa F, Smith L, Shen Y, et al. Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy. Mol Ther. 2019;27:878\u201389.","journal-title":"Mol Ther"},{"key":"723_CR78","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","volume":"104","author":"X Zhu","year":"2019","unstructured":"Zhu X, Yin L, Theisen M, et al. Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates. Am J Hum Genet. 2019;104:625\u201337.","journal-title":"Am J Hum Genet"},{"key":"723_CR79","first-page":"106","volume":"13","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Liu Q, Deng Z, et al. Evaluating the metabolic basis of \u03b1-Gal A mRNA therapy for Fabry disease. Biology (Basel). 2024;13:106.","journal-title":"Biology (Basel)."},{"key":"723_CR80","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/adhm.201500746","volume":"5","author":"I Cabrera","year":"2016","unstructured":"Cabrera I, Abasolo I, Corchero JL, et al. \u03b1-Galactosidase-A loaded-nanoliposomes with enhanced enzymatic activity and intracellular penetration. Adv Healthc Mater. 2016;5:829\u201340.","journal-title":"Adv Healthc Mater."},{"key":"723_CR81","doi-asserted-by":"publisher","first-page":"eadq4738","DOI":"10.1126\/sciadv.adq4738","volume":"10","author":"J Tomsen-Melero","year":"2024","unstructured":"Tomsen-Melero J, Molt\u00f3-Abad M, Merlo-Mas J. Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease. Sci Adv. 2024;10:eadq4738.","journal-title":"Sci Adv"},{"key":"723_CR82","doi-asserted-by":"publisher","first-page":"25741","DOI":"10.1021\/acsami.6b08356","volume":"8","author":"MI Giannotti","year":"2016","unstructured":"Giannotti MI, Abasolo I, Oliva M, et al. Highly versatile polyelectrolyte complexes for improving the enzyme replacement therapy of lysosomal storage disorders. ACS Appl Mater Interfaces. 2016;8:25741\u201352.","journal-title":"ACS Appl Mater Interfaces"},{"key":"723_CR83","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ppsc.201500156","volume":"32","author":"M Nazarenus","year":"2015","unstructured":"Nazarenus M, Abasolo I, Garc\u00eda-Aranda N, et al. Polymer capsules as a theranostic tool for a universal in vitro screening assay: the case of lysosomal storage diseases. Part Syst Charact. 2015;32:991\u20138.","journal-title":"Part Syst Charact"},{"key":"723_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1684","volume":"13","author":"I Abasolo","year":"2021","unstructured":"Abasolo I, Seras-Franzoso J, Molt\u00f3-Abad M, et al. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13: e1684.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol."},{"key":"723_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12058","volume":"10","author":"J Seras-Franzoso","year":"2021","unstructured":"Seras-Franzoso J, D\u00edaz-Riascos ZV, Corchero JL, et al. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders. J Extracell Vesicles. 2021;10: e12058.","journal-title":"J Extracell Vesicles."},{"key":"723_CR86","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199302183280701","volume":"328","author":"JM Lusher","year":"1993","unstructured":"Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. N Engl J Med. 1993;328:453\u20139.","journal-title":"N Engl J Med"},{"key":"723_CR87","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66:1589\u201395.","journal-title":"Kidney Int"},{"key":"723_CR88","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/nbt.1484","volume":"26","author":"J Wang","year":"2008","unstructured":"Wang J, Lozier J, Johnson G, Kirshner S, Verthelyi D, Pariser A, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol. 2008;26:901\u20138.","journal-title":"Nat Biotechnol"},{"key":"723_CR89","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","volume":"101","author":"JM de Vries","year":"2010","unstructured":"de Vries JM, van der Beek NAME, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101:338\u201345.","journal-title":"Mol Genet Metab"},{"key":"723_CR90","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, et al. Anti-a-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab. 2012;105:443\u20139.","journal-title":"Mol Genet Metab"},{"key":"723_CR91","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","volume":"108","author":"BE Smid","year":"2013","unstructured":"Smid BE, Hoogendijk SL, Wijburg FA, Hollak CE, Linthorst GE. A revised home treatment algorithm for Fabry disease: influence of antibody formation. Mol Genet Metab. 2013;108:132\u20137.","journal-title":"Mol Genet Metab"},{"key":"723_CR92","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.3390\/ijms21165784","volume":"21","author":"SJ van der Veen","year":"2020","unstructured":"van der Veen SJ, Vlietstra WJ, et al. Predicting the development of anti-drug antibodies against recombinant alpha-galactosidase A in male patients with classical Fabry disease. Int J Mol Sci. 2020;21:5784.","journal-title":"Int J Mol Sci"},{"key":"723_CR93","first-page":"109","volume":"5","author":"K Nicholls","year":"2012","unstructured":"Nicholls K, Bleasel K, Becker G. Severe infusion reactions to Fabry enzyme replacement therapy: rechallenge after tracheostomy. JIMD Rep. 2012;5:109\u201312.","journal-title":"JIMD Rep."},{"key":"723_CR94","first-page":"367","volume":"23","author":"O Aydin","year":"2013","unstructured":"Aydin O, Kasapkara CS, Celik GE. Successful desensitization with agalsidase alfa in 2 brothers with Fabry disease. J Investig Allergol Clin Immunol. 2013;23:367\u20138.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"723_CR95","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/ijms21197213","volume":"21","author":"RP Limgala","year":"2020","unstructured":"Limgala RP, Fikry J, Veligatla V, Goker-Alpan O. The interaction of innate and adaptive ammunity and stabilization of mast cell activation in management of infusion related reactions in patients with Fabry disease. Int J Mol Sci. 2020;21:7213.","journal-title":"Int J Mol Sci"},{"key":"723_CR96","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.anai.2020.08.026","volume":"126","author":"I DuBuske","year":"2021","unstructured":"DuBuske I, Schmidlin K, Bernstein JA. Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment. Ann Allergy Asthma Immunol. 2021;126:96.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"723_CR97","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, International Fabry Disease Study Group, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75:65\u201374.","journal-title":"Am J Hum Genet"},{"key":"723_CR98","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77\u201386.","journal-title":"Ann Intern Med"},{"key":"723_CR99","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","volume":"10","author":"D Bodensteiner","year":"2008","unstructured":"Bodensteiner D, Scott CR, Sims KB, et al. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med. 2008;10:353\u20138.","journal-title":"Genet Med"},{"key":"723_CR100","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","volume":"152","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr. 2008;152:563\u201370.","journal-title":"J Pediatr"},{"issue":"Suppl. 3","key":"723_CR101","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1007\/s10545-010-9136-0","volume":"33","author":"A Tanaka","year":"2010","unstructured":"Tanaka A, Takeda T, Hoshina T, Fukai K, Yamano T. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha. J Inherit Metab Dis. 2010;33(Suppl. 3):S249\u201352.","journal-title":"J Inherit Metab Dis"},{"key":"723_CR102","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1939-4551-7-9","volume":"7","author":"FE Simons","year":"2014","unstructured":"Simons FE, Ardusso LR, Bil\u00f2 MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014;7:9.","journal-title":"World Allergy Organ J"},{"key":"723_CR103","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/WOX.0b013e318211496c","volume":"4","author":"FE Simons","year":"2011","unstructured":"Simons FE, Ardusso LR, Bil\u00f2 MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4:13\u201337.","journal-title":"World Allergy Organ J"},{"key":"723_CR104","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.iac.2009.04.012","volume":"29","author":"M Castells","year":"2009","unstructured":"Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am. 2009;29:585\u2013606.","journal-title":"Immunol Allergy Clin North Am"},{"key":"723_CR105","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.1044","author":"TW Jimenez-Rodriguez","year":"2024","unstructured":"Jimenez-Rodriguez TW, Soriano Gomis V, Burgos San-Jos\u00e9 A, et al. A 1-bag\/4-step rapid desensitization protocol to reintroduce agalsidase a in a patient with Fabry disease. J Investig Allergol Clin Immunol. 2024. https:\/\/doi.org\/10.18176\/jiaci.1044.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"723_CR106","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","volume":"141","author":"M Lenders","year":"2018","unstructured":"Lenders M, Schmitz B, Brand SM, Foell D, Brand E. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. J Allergy Clin Immunol. 2018;141:2289-92.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR107","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/jimd.12176","volume":"43","author":"F Stappers","year":"2020","unstructured":"Stappers F, Scharnetzki D, Schmitz B, et al. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity. J Inherit Metab Dis. 2020;43:334\u201347.","journal-title":"J Inherit Metab Dis"},{"key":"723_CR108","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neu\u00dfer LP, Rudnicki M, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2879\u201389.","journal-title":"J Am Soc Nephrol"},{"key":"723_CR109","doi-asserted-by":"publisher","first-page":"1024963","DOI":"10.3389\/fimmu.2022.1024963","volume":"13","author":"M Lenders","year":"2022","unstructured":"Lenders M, Brand E. Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease. Front Immunol. 2022;13:1024963.","journal-title":"Front Immunol"},{"key":"723_CR110","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.omtm.2022.07.009","volume":"26","author":"M Lenders","year":"2022","unstructured":"Lenders M, Pollmann S, Terlinden M, Brand E. Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa. Mol Ther Methods Clin Dev. 2022;26:323\u201330.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"723_CR111","doi-asserted-by":"publisher","first-page":"1266082","DOI":"10.3389\/fimmu.2023.1266082","volume":"14","author":"M Lenders","year":"2023","unstructured":"Lenders M, Feidicker LM, Brand SM, Brand E. Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease. Front Immunol. 2023;14:1266082.","journal-title":"Front Immunol"},{"key":"723_CR112","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","volume":"88","author":"BM Chen","year":"2016","unstructured":"Chen BM, Su YC, Chang CJ, et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem. 2016;88:10661\u20136.","journal-title":"Anal Chem"},{"key":"723_CR113","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju Y, Lee WS, Pilkington EH, et al. Anti-PEG antibodies boosted in humans by SARS-coV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16:11769\u201380.","journal-title":"ACS Nano"},{"key":"723_CR114","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","volume":"23","author":"Y Ju","year":"2023","unstructured":"Ju Y, Carre\u00f1o JM, Simon V, et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat Rev Immunol. 2023;23:135\u20136.","journal-title":"Nat Rev Immunol"},{"key":"723_CR115","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","volume":"114","author":"TE Hunley","year":"2004","unstructured":"Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics. 2004;114:e532\u20135.","journal-title":"Pediatrics"},{"key":"723_CR116","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1681\/ASN.2013030290","volume":"25","author":"H Debiec","year":"2014","unstructured":"Debiec H, Valayannopoulos V, Boyer O, et al. Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. J Am Soc Nephrol. 2014;25:675\u201380.","journal-title":"J Am Soc Nephrol"},{"key":"723_CR117","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","volume":"385","author":"P Ronco","year":"2015","unstructured":"Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient\u2019s care. Lancet. 2015;385:1983\u201392.","journal-title":"Lancet"},{"key":"723_CR118","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1542\/peds.100.6.e11","volume":"100","author":"RO Brady","year":"1997","unstructured":"Brady RO, Murray GJ, Oliver KL, et al. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics. 1997;100:E11.","journal-title":"Pediatrics"},{"key":"723_CR119","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94328","volume":"2","author":"ZB Kazi","year":"2017","unstructured":"Kazi ZB, Desai AK, Berrier KL, et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017;2: e94328.","journal-title":"JCI Insight."},{"key":"723_CR120","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc0806809","volume":"360","author":"NJ Mendelsohn","year":"2009","unstructured":"Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease. N Engl J Med. 2009;360:194\u20135.","journal-title":"N Engl J Med"},{"key":"723_CR121","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","volume":"105","author":"SG Banugaria","year":"2012","unstructured":"Banugaria SG, Patel TT, Mackey J, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody- secreting plasma cells. Mol Genet Metab. 2012;105:677\u201380.","journal-title":"Mol Genet Metab"},{"key":"723_CR122","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","volume":"15","author":"SG Banugaria","year":"2013","unstructured":"Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2013;15:123\u201331.","journal-title":"Genet Med"},{"key":"723_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067052","volume":"8","author":"SG Banugaria","year":"2013","unstructured":"Banugaria SG, Prater SN, Patel TT, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. PLoS ONE. 2013;8: e67052.","journal-title":"PLoS ONE"},{"key":"723_CR124","first-page":"11","volume":"2","author":"J Markic","year":"2012","unstructured":"Markic J, Polic B, Kuzmanic-Samija R, et al. Immune modulation therapy in a CRIM-positive and IgG antibody positive infant with Pompe disease treated with alglucosidase alpha: a case report. JIMD Rep. 2012;2:11\u20135.","journal-title":"JIMD Rep."},{"key":"723_CR125","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","volume":"163","author":"ME Elder","year":"2013","unstructured":"Elder ME, Nayak S, Collins SW, et al. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2013;163:847-54.e1.","journal-title":"J Pediatr"},{"key":"723_CR126","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00508-013-0475-3","volume":"126","author":"J Markic","year":"2014","unstructured":"Markic J, Polic B, Stricevic L, et al. Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study. Wien Klin Wochenschr. 2014;126:133\u20137.","journal-title":"Wien Klin Wochenschr"},{"key":"723_CR127","first-page":"20","volume":"2","author":"KH Kim","year":"2014","unstructured":"Kim KH, Messinger YH, Burton BK. Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II. Mol Genet Metab Rep. 2014;2:20\u20134.","journal-title":"Mol Genet Metab Rep."},{"key":"723_CR128","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fimmu.2020.01000","volume":"11","author":"DC Julien","year":"2020","unstructured":"Julien DC, Woolgar K, Pollard L, et al. Immune modulation for enzyme replacement therapy in a female patient with Hunter syndrome. Front Immunol. 2020;11:1000.","journal-title":"Front Immunol"},{"key":"723_CR129","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, Oder D, Nowak A, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017;282:241\u201353.","journal-title":"J Intern Med"},{"key":"723_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2022.104641","volume":"382","author":"J Rana","year":"2022","unstructured":"Rana J, Mu\u00f1oz MM, Biswas M. Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies. Cell Immunol. 2022;382: 104641.","journal-title":"Cell Immunol"},{"key":"723_CR131","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2016.05.027","volume":"139","author":"BP Vickery","year":"2017","unstructured":"Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139:173-81.e8.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR132","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jaip.2017.09.016","volume":"6","author":"JA Bird","year":"2018","unstructured":"Bird JA, Spergel JM, Jones SM, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6:476\u201385.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"723_CR133","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1467-7652.2011.00613.x","volume":"9","author":"K Suzuki","year":"2011","unstructured":"Suzuki K, Kaminuma O, Yang L, et al. Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression. Plant Biotechnol J. 2011;9:982\u201390.","journal-title":"Plant Biotechnol J"},{"key":"723_CR134","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/cmi.2011.13","volume":"8","author":"CC Lee","year":"2011","unstructured":"Lee CC, Ho H, Lee KT, Jeng ST, Chiang BL. Construction of a Der p2-transgenic plant for the alleviation of airway inflammation. Cell Mol Immunol. 2011;8:404\u201314.","journal-title":"Cell Mol Immunol"},{"key":"723_CR135","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/pbi.12007","volume":"11","author":"Y Wakasa","year":"2013","unstructured":"Wakasa Y, Takagi H, Hirose S, et al. Oral immunotherapy with transgenic rice seed containing destructed Japanese cedar pollen allergens, Cry j 1 and Cry j 2, against Japanese cedar pollinosis. Plant Biotechnol J. 2013;11:66\u201376.","journal-title":"Plant Biotechnol J"},{"key":"723_CR136","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/pbi.12413","volume":"13","author":"J Su","year":"2015","unstructured":"Su J, Sherman A, Doerfler PA, Byrne BJ, Herzog RW, Daniell H. Oral delivery of acid alpha glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnol J. 2015;13:1023\u201332.","journal-title":"Plant Biotechnol J"},{"key":"723_CR137","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1182\/blood-2013-10-528737","volume":"124","author":"A Sherman","year":"2014","unstructured":"Sherman A, Su J, Lin S, Wang X, Herzog RW, Daniell H. Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells. Blood. 2014;124:1659\u201368.","journal-title":"Blood"},{"key":"723_CR138","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.biomaterials.2015.08.004","volume":"70","author":"J Su","year":"2015","unstructured":"Su J, Zhu L, Sherman A, et al. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials. 2015;70:84\u201393.","journal-title":"Biomaterials"},{"key":"723_CR139","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ymthe.2016.11.009","volume":"25","author":"RW Herzog","year":"2017","unstructured":"Herzog RW, Nichols TC, Su J, et al. Oral tolerance induction in hemophilia B dogs fed with transplastomic lettuce. Mol Ther. 2017;25:512\u201322.","journal-title":"Mol Ther"},{"key":"723_CR140","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/pbi.12859","volume":"16","author":"KC Kwon","year":"2018","unstructured":"Kwon KC, Sherman A, Chang WJ, et al. Expression and assembly of largest foreign protein in chloroplasts: oral delivery of human FVIII made in lettuce chloroplasts robustly suppresses inhibitor formation in haemophilia A mice. Plant Biotechnol J. 2018;16:1148\u201360.","journal-title":"Plant Biotechnol J"},{"key":"723_CR141","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","volume":"56","author":"M Lenders","year":"2019","unstructured":"Lenders M, Stappers F, Niemietz C, et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. J Med Genet. 2019;56:548\u201356.","journal-title":"J Med Genet"},{"key":"723_CR142","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cpt.1321","volume":"105","author":"J M\u00fcntze","year":"2019","unstructured":"M\u00fcntze J, Gensler D, Maniuc O, et al. Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharmacol Ther. 2019;105:1224\u201333.","journal-title":"Clin Pharmacol Ther"},{"key":"723_CR143","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.1832","volume":"108","author":"M Lenders","year":"2020","unstructured":"Lenders M, Nordbeck P, Kurschat C, et al. Treatment of Fabry\u2019s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS). Clin Pharmacol Ther. 2020;108:326\u201337.","journal-title":"Clin Pharmacol Ther"},{"key":"723_CR144","doi-asserted-by":"publisher","first-page":"1220637","DOI":"10.3389\/fmed.2023.1220637","volume":"10","author":"DG Bichet","year":"2023","unstructured":"Bichet DG, Hopkin RJ, Aguiar P, et al. Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study. Front Med (Lausanne). 2023;10:1220637.","journal-title":"Front Med (Lausanne)."},{"key":"723_CR145","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375:545\u201355.","journal-title":"N Engl J Med"},{"key":"723_CR146","doi-asserted-by":"publisher","first-page":"21928","DOI":"10.1016\/j.ymgme.2020.07.007","volume":"131","author":"U Feldt-Rasmussen","year":"2020","unstructured":"Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131:21928.","journal-title":"Mol Genet Metab"},{"key":"723_CR147","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","volume":"8","author":"M Lenders","year":"2022","unstructured":"Lenders M, Nordbeck P, Kurschat C, et al. Treatment of Fabry disease management with migalastat outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother. 2022;8:272\u201381.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"723_CR148","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"JQ Fan","year":"1999","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5:112\u20135.","journal-title":"Nat Med"},{"key":"723_CR149","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","volume":"267","author":"N Asano","year":"2000","unstructured":"Asano N, Ishii S, Kizu H, et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem. 2000;267:4179\u201386.","journal-title":"Eur J Biochem"},{"key":"723_CR150","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40259-024-00678-x","volume":"38","author":"M Lenders","year":"2024","unstructured":"Lenders M, Menke ER, Brand E. Biochemical amenability in Fabry patients under chaperone therapy: how and when to test? BioDrugs. 2024;38:845\u201354.","journal-title":"BioDrugs"},{"key":"723_CR151","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27:1042\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"723_CR152","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Thomas CP, Vujkovac B, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet. 2015;52:860\u20136.","journal-title":"J Med Genet"},{"key":"723_CR153","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/ki.1997.394","volume":"52","author":"JM De'Oliveira","year":"1997","unstructured":"De\u2019Oliveira JM, Price DA, Fisher ND, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int. 1997;52:771\u20137.","journal-title":"Kidney Int"},{"key":"723_CR154","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1681\/ASN.2011040430","volume":"23","author":"S Vegter","year":"2012","unstructured":"Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol. 2012;23:165\u201373.","journal-title":"J Am Soc Nephrol"},{"key":"723_CR155","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2019","unstructured":"Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and investigational therapeutics for Fabry disease. Kidney Int Rep. 2019;5:407\u201313.","journal-title":"Kidney Int Rep."},{"issue":"105","key":"723_CR156","first-page":"S117","volume":"2024","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;2024(105):S117-314.","journal-title":"Kidney Int"},{"key":"723_CR157","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/jcm12113689","volume":"12","author":"Y Battaglia","year":"2023","unstructured":"Battaglia Y, Bulighin F, Zerbinati L, Vitturi N, Marchi G, Carraro G. Dapaglifozin on albuminuria in chronic kidney disease patients with Fabry disease: the DEFY study design and protocol. J Clin Med. 2023;12:3689.","journal-title":"J Clin Med"},{"key":"723_CR158","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13023-023-02796-1","volume":"18","author":"KM Stepien","year":"2023","unstructured":"Stepien KM, Broomfield A, Cole D, et al. Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel. Orphanet J Rare Dis. 2023;18:203.","journal-title":"Orphanet J Rare Dis"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00723-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T12:01:56Z","timestamp":1750680116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00723-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":158,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00723-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"9 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Malte Lenders received research grants and\/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Sumitomo Pharma, and Takeda. Eva Brand received research grants and\/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Takeda, and Eleva. Elise Raphaela Menke has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The original contributions presented in the study are included in the article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ML, ERM, and EB wrote the manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}